Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Rodri joins La Liga champions Barcelona from Manchester City
-
France's first women's rights minister Yvette Roudy dies, aged 97
-
Disney, ABC sue US regulator over threat to broadcast licenses
-
French producer Nicolas Altmayer, Dior PR chief Favier die in car crash
-
Trump, Carney hold talks as new US tariffs on Canada loom
-
Bezos consortium bought nearly 40 percent of Liverpool: report
-
Germany opens new drone research centre as security threats mount
-
Trump says no Iran talks planned, claims Hormuz 'new US territory'
-
How only a few tree species drive Amazon forest recovery
-
Canada seeks to avert new US tariffs as deadline looms
-
Ivonne A-Baki enters race to be next UN chief
-
US primaries test Democrat comeback hopes in Trump stronghold
-
Ukraine says Russian strike kills 10 in northeast region
-
Scientists discover how narwhals grow nature's only straight tusk
-
Meta in court over child social media addiction
-
DR Congo Ebola outbreak 'far from being under control': WHO chief
-
Vieira appointed Senegal head coach after World Cup disappointment
-
Firefighters in 'decisive' push to encircle Belgian wildfire
-
F1's Albon re-signs with Williams for 2027
-
Tribal Partners with ServiceNow to Empower Enterprise Teams to Build and Deploy Apps & Agents
-
Borderless.xyz Deepens Africa Coverage as CrissCross Goes Live on Its Network
-
Fusion Markets Extends Negative Balance Protection to Clients Globally
-
Pakistan court orders ex-PM Khan moved from jail to hospital
-
India close on victory in first Test against Sri Lanka
-
'Lonely place': Black UK academics slam racism after Arday's death
-
Three lightly injured as new quake hits Spain's Granada
-
UK PM says not embarrassed by hoax messages with fake Trump aide
-
Syria, US say Israel struck military air base in Idlib province
-
West Bank siege exposes Israel army inaction on settler violence
-
France probes Russian disinfo campaign against centrist candidates
-
Four-time champion Roglic to ride Vuelta after training crash
-
Stocks mostly drop as Mideast hopes dim, interest rates rise
-
Ukrainian convicted in Germany over Russian sabotage plot
-
Bayern's Musiala returns to training after on-field collapse
-
Beleaguered FIFA chief Infantino rids himself of critic Lamour
-
China's Baidu, betting on AI, posts fifth straight quarterly revenue drop
-
Kane confirms Bayern extension talks set to start
-
German farmers warn of drought toll on grain harvest
-
Asian allies stress 'critical' US cooperation as Trump slashes Korea drills
-
Pant fastest to 100 sixes as India set Sri Lanka 372 to win first Test
-
Pakistan Supreme Court orders ex-PM Khan moved from jail to hospital
-
Russia rebukes Japan ambassador over disputed islands row
-
Firefighters push to 'encircle' Belgian wildfire
-
Crude extends gains, most stocks drop as Mideast hopes dim
-
ISS to host first spacewalk by Frenchwoman
-
Rift deepens as Asia football chief hits back at Qatar in Infantino saga
-
Philippine student killed in livestreamed school shooting
-
India extend lead to 294 in first Sri Lanka Test
-
More Trump-Kim 'love'? What we know about North Korea
-
Asian allies stress 'critical cooperation' as Trump slashes Korea drills
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
O.Salim--SF-PST